Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 7/20 | 0.80 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.80 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.80 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.80 |
| ▸ | SRC | P12931 | 2/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.80 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.80 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.80 |
| ▸ | TRPM2 | O94759 | 2/20 | 0.75 |
| ▸ | MACROD2 | A1Z1Q3 | 1/20 | 0.75 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.75 |
| ▸ | MACROD1 | Q9BQ69 | 1/20 | 0.75 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.69 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.69 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.69 |
| ▸ | LDHA | P00338 | 1/20 | 0.69 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.69 |
| ▸ | FBP1 | P09467 | 1/20 | 0.69 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14017398 | 0.93 | P2RY1 (0.80) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 | |
| SCHEMBL13614610 | 0.93 | P2RY1 (0.80) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 | |
| SCHEMBL2057822 | 0.93 | P2RY1 (0.80) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 | |
| SCHEMBL2057152 | 0.93 | P2RY1 (0.83) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 | |
| SCHEMBL9098744 | 0.93 | P2RY1 (0.82) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 | |
| SCHEMBL2164937 | 0.92 | P2RY1 (0.78) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 | |
| SCHEMBL2057161 | 0.92 | P2RY1 (0.80) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 | |
| SCHEMBL772527 | 0.92 | P2RY1 (0.80) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 | |
| SCHEMBL2057448 | 0.92 | P2RY1 (0.80) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 | |
| SCHEMBL2165989 | 0.90 | P2RY1 (0.78) | P2RY1P2RY2P2RX1P2RX3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7211414-B2 | Enzymatic nucleic acid synthesis: compositions and methods for altering monomer incorporation fidelity | VISIGEN BIOTECHNOLOGIES, INC. (US) | 2007-05-01 | — | — | US | claimed |
| EP-3415641-B1 | METHOD FOR ANALYSIS OF MOLECULES | PACIFIC BIOSCIENCES CALIFORNIA INC (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-3415641-A1 | METHOD FOR ANALYSIS OF MOLECULES | Pacific Biosciences Of California, Inc. (US) | 2018-12-19 | — | — | EP | disclosed |
| US-20180100191-A1 | ENZYMATIC NUCLEIC ACID SYNTHESIS: COMPOSITIONS AND METHODS FOR INHIBITING PYROPHOSPHOROLYSIS | VISIGEN BIOTECHNOLOGIES, INC. | 2018-04-12 | — | — | US | disclosed |
| US-9845500-B2 | Enzymatic nucleic acid synthesis: compositions and methods for inhibiting pyrophosphorolysis | Life Technologies Corporation (US) | 2017-12-19 | — | — | US | disclosed |
| US-20160244822-A1 | ENZYMATIC NUCLEIC ACID SYNTHESIS: COMPOSITIONS AND METHODS FOR INHIBITING PYROPHOSPHOROLYSIS | Life Technologies Corporation | 2016-08-25 | — | — | US | disclosed |
| US-9243284-B2 | Enzymatic nucleic acid synthesis: compositions and methods for inhibiting pyrophosphorolysis | Life Technologies Corporation (US) | 2016-01-26 | — | — | US | disclosed |
| US-20140127781-A1 | ENZYMATIC NUCLEIC ACID SYNTHESIS: COMPOSITIONS AND METHODS FOR INHIBITING PYROPHOSPHOROLYSIS | Life Technologies Corporation (US) | 2014-05-08 | — | — | US | disclosed |
| US-8709725-B2 | Arrays of optical confinements and uses thereof | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-8648179-B2 | Enzymatic nucleic acid synthesis: compositions and methods for inhibiting pyrophosphorolysis | Life Technologies Corporation (US) | 2014-02-11 | — | — | US | disclosed |
| US-20070172860-A1 | Enzymatic nucleic acid synthesis: compositions and methods | Life Technologies Corporation | 2007-07-26 | — | — | US | disclosed |
| US-20070172869-A1 | Enzymatic nucleic acid synthesis: methods for inhibiting pyrophosphorolysis during sequencing synthesis | Life Technologies Corporation | 2007-07-26 | — | — | US | disclosed |
| US-20070172819-A1 | Enzymatic nucleic acid synthesis: compositions including pyrophosphorolysis inhibitors | Life Technologies Corporation | 2007-07-26 | — | — | US | disclosed |
| EP-1790202-A2 | APPARATUS AND METHOD FOR ANALYSIS OF MOLECULES | Pacific Biosciences of California, Inc. (US) | 2007-05-30 | — | — | EP | disclosed |
| US-7211414-B2 | Enzymatic nucleic acid synthesis: compositions and methods for altering monomer incorporation fidelity | VISIGEN BIOTECHNOLOGIES, INC. (US) | 2007-05-01 | — | — | US | disclosed |
| WO-2006044078-A2 | APPARATUS AND METHOD FOR ANALYSIS OF MOLECULES | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| EP-1354064-A2 | ENZYMATIC NUCLEIC ACID SYNTHESIS: COMPOSITIONS AND METHODS FOR ALTERING MONOMER INCORPORATION FIDELITY | Visigen Biotechnologies, Inc. (US) | 2003-10-22 | — | — | EP | disclosed |
| US-20030134807-A1 | Enzymatic nucleic acid synthesis: compositions and methods for altering monomer incorporation fidelity | Life Technologies Corporation | 2003-07-17 | — | — | US | disclosed |
| WO-2002044425-A2 | ENZYMATIC NUCLEIC ACID SYNTHESIS: COMPOSITIONS AND METHODS FOR ALTERING MONOMER INCORPORATION FIDELITY | VISIGEN BIOTECHNOLOGIES, INC. (US) | 2002-06-06 | — | — | WO | disclosed |
| US-6399335-B1 | MIXING POLYMERASE AND NUCLEOSIDE TRIPHOSPHATE HAVING A GAMMA PHOSPHATE PHOSPHOESTER-LINKED FUNCTIONAL GROUP, INCUBATING SO THAT POLYMERASE CATALYZES CLEAVAGE BETWEEN ALPHA AND BETA PHOSPHATES AND LIBERATES PYROPHOSPHATE WITH FUNCTIONAL GROUP | ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE, INC. | 2002-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070172819-A1 | Enzymatic nucleic acid synthesis: compositions including pyrophosphorolysis inhibitors | RNGTT, PPA1, PNP | P2RY1 258/4885P2RY2 519/4885P2RX1 520/4885 |
| US-20180100191-A1 | ENZYMATIC NUCLEIC ACID SYNTHESIS: COMPOSITIONS AND METHODS FOR INHIBITING PYROPHOSPHOROLYSIS | RNGTT, PPA1, PNP | P2RY1 292/4885P2RY2 543/4885P2RX1 570/4885 |
| US-20030134807-A1 | Enzymatic nucleic acid synthesis: compositions and methods for altering monomer incorporation fidelity | RNGTT, PNP, MTAP | P2RY1 574/4885P2RY2 1301/4885P2RX1 1291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.